Ajaypal Singh to Diabetes Mellitus, Type 2
This is a "connection" page, showing publications Ajaypal Singh has written about Diabetes Mellitus, Type 2.
Connection Strength
1.708
-
Introduction: A Multi-Pronged Approach to CKD Associated With Type 2 Diabetes. Semin Nephrol. 2023 05; 43(3):151444.
Score: 0.776
-
Diabetes, anemia and CKD: Why TREAT? Curr Diab Rep. 2010 Aug; 10(4):291-6.
Score: 0.309
-
Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2019 05; 21(5):1199-1208.
Score: 0.140
-
ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type?2 Diabetic Patients With CKD. Am J Kidney Dis. 2017 Oct; 70(4):522-531.
Score: 0.124
-
Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm. Am J Kidney Dis. 2013 Feb; 61(2):238-46.
Score: 0.091
-
Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation. 2011 Dec 20; 124(25):2903-8.
Score: 0.085
-
Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med. 2010 Sep 16; 363(12):1146-55.
Score: 0.078
-
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009 Nov 19; 361(21):2019-32.
Score: 0.073
-
Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis. 2009 Jul; 54(1):59-69.
Score: 0.018
-
Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J. 2005 Mar; 149(3):408-13.
Score: 0.013